Skip to main content

Advertisement

Table 4 Baseline clinical and demographic predictors of uveitis in 435 participants in the Nordic juvenile idiopathic arthritis (JIA) cohort

From: Incidence and predictors of Uveitis in juvenile idiopathic arthritis in a Nordic long-term cohort study

  No uveitis Uveitis OR (95% CI)
N n (%) N n (%)  
Female gender 346 227 (65.6) 89 59 (66.3) 1.0 (0.6, 1.6)
Oligoarticular onset 346 168 (48.6) 89 41 (46.1) 0.9 (0.6, 1.4)
Age at onset (< 7 years) 346 189 (54.6) 89 64 (71.9) 2.1 (1.3, 3.5)
ANA positive 340 79 (23.2) 87 37 (42.5) 2.4 (1.5, 4.0)
AHA > 15 U 112 14 (12.5) 22 9 (40.9) 4.8 (1.8, 13.4)
HLA-B27 positive 325 62 (19.1) 87 25 (28.7) 1.7 (1.0, 2.9)
ESR > 20 mm/H 276 95 (34.4) 78 34 (43.6) 1.5 (0.9, 2.5)
CRP > 10 mg/L 276 77 (27.9) 74 27 (36.5) 1.5 (0.9, 2.6)
DMARD use ≤ 2nd visita 316 111 (35.1) 34 14 (41.2) 1.3 (0.6, 2.7)
  1. aIn 350 children with no uveitis at the time of 2nd study visit, percentage of DMARD used within 2nd visit (median 13 (1st q 12, 3rd q 14) months) in children with no uveitis versus children with uveitis during further follow-up.
  2. Odds ratio (OR) of developing uveitis calculated with logistic regression. Oligoarticular onset, oligoarticular category 6 months after onset of disease, according to the International League of Associations for Rheumatology (ILAR) classification criteria (5); ANA antinuclear antibodies measured by immunofluorescence on Hep-2 cells two positive tests taken > 3 months apart in participants with one or more tests taken